嵌合抗原受体修饰T细胞制品的开发及其临床应用面临的挑战  

Development of chimeric antigen receptor T cell products and challenges encountered in clinical application

作　　者：王冲 

机构地区：[1]上海药品审评核查中心,上海201203

出　　处：《药学服务与研究》2017年第4期275-278,共4页Pharmaceutical Care and Research

摘　　要：嵌合抗原受体修饰T细胞(chimeric antigen receptor T cell,CAR-T)制品在肿瘤免疫治疗方面取得了显著效果,尤其是在B细胞恶性肿瘤病人中有较高的客观缓解率。本文对CAR-T细胞制品规模生产的可行性、病毒载体的选择,其临床应用面临的挑战及应对策略做一综述。Chimeric antigen receptor T cell （CAR-T ） products have achieved obvious effects in tumor immunotherapy . CAR-T cell therapy has shown high objective response rates,especially in the patients with B lymphocyte malignance .The feasibility of industrial production,choice of viral vector,challenges encountered in clinical application and strategies for the development of CAR-T cell products were reviewed in the paper.

关 键 词：嵌合抗原受体修饰T细胞 药品研发 临床应用 综述 

分 类 号：R979.1[医药卫生—药品] R944.9[医药卫生—药学]